MedTrace Logo

AdvanTIG-202: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Previously Treated Recurrent or Metastatic Cervical Cancer

NCT04693234 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 178

Last updated 2025-04-27

Study results available
· View outcomes & findings →

Summary

This study tested how well and how safely the drug tislelizumab, given either alone or with another drug called ociperlimab (BGB-A1217), worked in people with cervical cancer that had come back or spread after previous treatments. The study included two groups and took place at multiple medical centers.

Conditions

Interventions

BIOLOGICAL

Tislelizumab

200 mg administered intravenously once every 3 weeks on day 1 of each cycle

BIOLOGICAL

Ociperlimab

900 mg administered intravenously once every 3 weeks on day 1 of each cycle

Sponsors & Collaborators

  • BeiGene

    lead INDUSTRY

Principal Investigators

  • Study Director · BeiGene

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-15
Primary Completion
2022-06-16
Completion
2023-08-31

Countries

  • Bulgaria
  • China
  • Poland
  • Russia
  • South Korea
  • Taiwan
  • Thailand
  • Ukraine

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04693234 on ClinicalTrials.gov